These brain scan images provided by Biogen show how high levels of Alzheimer's-related tau protein, in red, dropped in a recipient of the company's experimental drug diranersen. (Biogen via AP)
From
To
An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau. Today two Alzheimer's drugs can modestly slow cognitive decline by clearing away buildup of a different protein, amyloid. But tau plays a role, too, and there are no tau-targeting drugs. Researchers at the Alzheimer's Association International Conference reported new findings Tuesday suggesting Biogen's experimental drug diranersen also might offer that benefit. The company plans a larger study to tell. It's one of multiple novel, but early-stage, attempts to fight the mind-robbing disease.
Delaware State Police say four siblings were located after a Gold Alert was issued for them Monday.
There’s a plethora of words to use when describing these last few months. There’s many emotions and feelings, but I […]
The Alzheimer’s Association reports every 65 seconds, someone in this country develops the disease. Dr. Michael Gitcho, an assistant professor at Delaware State […]
Today on DelmarvaLife – The Alzheimer’s Association reports every 65 seconds, someone in this country develops the disease. Dr. Michael […]
